prikaz prve stranice dokumenta Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry
  Download
PDF 1.15 MB
Scientific paper - Original scientific paper
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry
eClinicalMedicine, 58 (2023); 101939. https://doi.org/10.1016/j.eclinm.2023.101939
(EPICOVIDEHA registry) Salmanton-García, Jon; Marchesi, Francesco; Gomes da Silva, Maria; Farina, Francesca; Dávila-Valls, Julio; Bilgin, Yavuz M.; Glenthøj, Andreas; Falces-Romero, Iker; Van Doesum, Jaap; Labrador, Jorge; Buquicchio, Caterina; El-Ashwah, Shaimaa; Petzer, Verena; Van Praet, Jens; Schönlein, Martin; Dargenio, Michelina; Méndez, Gustavo-Adolfo; Meers, Stef; Itri, Federico; Giordano, Antonio; Pinczés, László Imre; Espigado, Ildefonso; Stojanoski, Zlate; López-García, Alberto; Prezioso, Lucia; Jaksic, Ozren; Vena, Antonio; Fracchiolla, Nicola S.; González-López, Tomás José; Colović, Natasa; Delia, Mario; Weinbergerová, Barbora; Marchetti, Monia; Marques de Almeida, Joyce; Finizio, Olimpia; Besson, Caroline; Biernat, Monika M.; Valković, Toni; Lahmer, Tobias; Cuccaro, Annarosa; Ormazabal-Vélez, Irati; Batinić, Josip; Fernández, Noemí; De Jonge, Nick; Tascini, Carlo; Anastasopoulou, Amalia N.; Duléry, Rémy; Del Principe, Maria Ilaria; Plantefeve, Gaëtan; Papa, Mario Virgilio; Nucci, Marcio; Jiménez, Moraima; Aujayeb, Avinash; Hernández-Rivas, José-Ángel; Merelli, Maria; Cattaneo, Chiara; Blennow, Ola; Nordlander, Anna; Cabirta, Alba; Varricchio, Gina; Sacchi, Maria Vittoria; Cordoba, Raul; Arellano, Elena; Gräfe, Stefanie K.; Wolf, Dominik; Emarah, Ziad; Ammatuna, Emanuele; Hersby, Ditte Stampe; Martín-Pérez, Sonia; Nunes Rodrigues, Raquel; Rahimli, Laman; Pagano, Livio; Cornely, Oliver A. More authors...

Cite this document

Salmanton García, J., Marchesi, F., Gomes da Silva, M., Farina, F., Dávila Valls, J., Bilgin, Y. M. ... Cornely, O. A. (2023). Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry. eClinicalMedicine, 58.. doi: 10.1016/j.eclinm.2023.101939

Salmanton García, Jon, et al. "Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry." eClinicalMedicine, vol. 58, 2023. https://doi.org/10.1016/j.eclinm.2023.101939

Salmanton García, Jon, Francesco Marchesi, Maria Gomes da Silva, Francesca Farina, Julio Dávila Valls, Yavuz M. Bilgin, Andreas Glenthøj, et al. "Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry." eClinicalMedicine 58 (2023). https://doi.org/10.1016/j.eclinm.2023.101939

Salmanton García, J., et al. (2023) 'Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry', eClinicalMedicine, 58. doi: 10.1016/j.eclinm.2023.101939

Salmanton García J, Marchesi F, Gomes da Silva M, Farina F, Dávila Valls J, Bilgin YM, and sur.. Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry. eClinicalMedicine [Internet]. 2023 April [cited 2024 October 04];58. doi: 10.1016/j.eclinm.2023.101939

J. Salmanton García, et al., "Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry", eClinicalMedicine, vol. 58, April 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:647221. [Accessed: 04 October 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry
AuthorJon Salmanton-García
AuthorFrancesco Marchesi
AuthorMaria Gomes da Silva
AuthorFrancesca Farina
AuthorJulio Dávila-Valls
AuthorYavuz M. Bilgin
AuthorAndreas Glenthøj
AuthorIker Falces-Romero
AuthorJaap Van Doesum
AuthorJorge Labrador
AuthorCaterina Buquicchio
AuthorShaimaa El-Ashwah
AuthorVerena Petzer
AuthorJens Van Praet
AuthorMartin Schönlein
AuthorMichelina Dargenio
AuthorGustavo-Adolfo Méndez
AuthorStef Meers
AuthorFederico Itri
AuthorAntonio Giordano
AuthorLászló Imre Pinczés
AuthorIldefonso Espigado
AuthorZlate Stojanoski
AuthorAlberto López-García
AuthorLucia Prezioso
AuthorOzren Jaksic
AuthorAntonio Vena
AuthorNicola S. Fracchiolla
AuthorTomás José González-López
AuthorNatasa Colović
AuthorMario Delia
AuthorBarbora Weinbergerová
AuthorMonia Marchetti
AuthorJoyce Marques de Almeida
AuthorOlimpia Finizio
AuthorCaroline Besson
AuthorMonika M. Biernat
AuthorToni Valković
AuthorTobias Lahmer
AuthorAnnarosa Cuccaro
AuthorIrati Ormazabal-Vélez
AuthorJosip Batinić
AuthorNoemí Fernández
AuthorNick De Jonge
AuthorCarlo Tascini
AuthorAmalia N. Anastasopoulou
AuthorRémy Duléry
AuthorMaria Ilaria Del Principe
AuthorGaëtan Plantefeve
AuthorMario Virgilio Papa
AuthorMarcio Nucci
AuthorMoraima Jiménez
AuthorAvinash Aujayeb
AuthorJosé-Ángel Hernández-Rivas
AuthorMaria Merelli
AuthorChiara Cattaneo
AuthorOla Blennow
AuthorAnna Nordlander
AuthorAlba Cabirta
AuthorGina Varricchio
AuthorMaria Vittoria Sacchi
AuthorRaul Cordoba
AuthorElena Arellano
AuthorStefanie K. Gräfe
AuthorDominik Wolf
AuthorZiad Emarah
AuthorEmanuele Ammatuna
AuthorDitte Stampe Hersby
AuthorSonia Martín-Pérez
AuthorRaquel Nunes Rodrigues
AuthorLaman Rahimli
AuthorLivio Pagano
AuthorOliver A. Cornely
CollaborationEPICOVIDEHA registry
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Background: Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/ritonavir treatment in a large cohort of the latter patients. Methods: This is a retrospective cohort study from the multicentre EPICOVIDEHA registry (NCT04733729) on patients with haematological malignancy, who were diagnosed with COVID-19 between January and September 2022. Patients receiving nirmatrelvir/ritonavir were compared to those who did not. A logistic regression was run to determine factors associated with nirmatrelvir/ritonavir administration in our sample. Mortality between treatment groups was assessed with Kaplan-Meier survival plots after matching all the patients with a propensity score. Additionally, a Cox regression was modelled to detect factors associated with mortality in patients receiving nirmatrelvir/ritonavir. Findings: A total of 1859 patients were analysed, 117 (6%) were treated with nirmatrelvir/ritonavir, 1742 (94%) were treated otherwise. Of 117 patients receiving nirmatrelvir/ritonavir, 80% had received ≥1 anti-SARS-CoV-2 vaccine dose before COVID-19 onset, 13% of which received a 2nd vaccine booster. 5% were admitted to ICU. Nirmatrelvir/ritonavir treatment was associated with the presence of extrapulmonary symptoms at COVID-19 onset, for example anosmia, fever, rhinitis, or sinusitis (aOR 2.509, 95%CI 1.448-4.347) and 2nd vaccine booster (aOR 3.624, 95%CI 1.619-8.109). Chronic pulmonary disease (aOR 0.261, 95%CI 0.093-0.732) and obesity (aOR 0.105, 95%CI 0.014-0.776) were not associated with nirmatrelvir/ritonavir use. After propensity score matching, day-30 mortality rate in patients treated with nirmatrelvir/ritonavir was 2%, significantly lower than in patients with SARS-CoV-2 directed treatment other than nirmatrelvir/ritonavir (11%, p = 0.036). No factor was observed explaining the mortality difference in patients after nirmatrelvir/ritonavir administration. Interpretation: Haematological malignancy patients were more likely to receive nirmatrelvir/ritonavir when reporting extrapulmonary symptoms or 2nd vaccine booster at COVID-19 onset, as opposed to chronic pulmonary disease and obesity. The mortality rate in patients treated with nirmatrelvir/ritonavir was lower than in patients with targeted drugs other than nirmatrelvir/ritonavir.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleeClinicalMedicine
Numberingvol. 58, 101939
p-ISSN2589-5370
DOIhttps://doi.org/10.1016/j.eclinm.2023.101939
URN:NBNurn:nbn:hr:105:647221
Publication2023-04
Document URLhttps://linkinghub.elsevier.com/retrieve/pii/S2589537023001165
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2023-12-11 12:39:10